![coronavirus]()
In the midst of the worst pandemic in 100 years, two drugs
are at the forefront for treating SARS-CoV-2. One, hydroxychloroquine, has been
in use for malaria and arthritis for years. Many doctors around the world claim
they’ve successfully treated COVID-19 patients with hydroxychloroquine.
The other drug, remdesivir, failed at treating Ebola, but
researchers are saying it will work for COVID-19.
Hydroxychloroquine costs about $10; remdesivir will cost
thousands of dollars. So how is remdesivir, which has shown in clinical trials to
have “no statistically meaningful benefit for survival” of COVID-19, managing
to shove hydroxychloroquine out of the running?
In a carefully laid-out, easy-to-understand analysis, Indian
researcher Jacob Puliyel pulls the curtains off what’s going on behind the
scenes to make it look like only the expensive drug should be approved.
SOURCE: Sunday
Guardian June 29, 2020